Abstract
It has been known since the early 1970’s that nonsteroidal antiinflammatory drugs (NSAIDs) exert their antinflammatory effects through the blocking of the synthesis of prostaglandins (PGs) by inhibiting cyclooxygenäse (COX).1 Cyclooxygenase was believed to be a single enzyme present constitutively in many tissues. It is believed to be involved in the maintenance of essential physiological function such as platelet aggregation, cytoprotection in the stomach and maintenance of normal kidney function. While inhibiting the production of proinflammatory prostaglandins at the inflammatory sites, NSAIDs also reduce the cytoprotective PGs in the gastrointestinal (GI) tract, leading to mechanism-based GI toxicity.2 The recent discovery of an inducible isoform of cyclooxygenase (COX-2) that is associated primarily with inflammation3–5 has led to the hypothesis that NSAID-in-duced toxicity in the GI tract may be caused by the inhibition of the beneficial constitutive isoform of cyclooxygenase (COX-1) in these tissues, while the antiinflammatory effect of NSAIDs is due to the inhibition of the inducible isoform (COX-2) at the inflammation site. A selective COX-2 inhibitor has the potential therefore to be an effective antiinflammatory drug with reduced GI toxicity compared to current NSAIDs.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
J.R. Vane, Nature, 231:232–235 (1971).
H. R. Herschman, Cancer and Metastasis Reviews, 13:241–256 (1994).
T. Hla,. K. Neilson, Proc. Natl. Acad. Sci. USA, 89:7384–7385 (1992).
W. Xie, D. L. Robertson, D. L. Simmons, Drug Devel. Res., 25:249–265 (1992).
D. A. Kujubu, B. S. Fletcher, B. C. Varnum, R. W. Lim, H. R. Herschman, J. Biol. Chem. 266:12866–12872 (1991).
K. R. Gans, W. Galbraith, R. J. Roman, S. P. Haber, J. S. Kerr, W. K. Schmidt, C. Smith, W. E. Hewes, N. R. Ackerman, J. Pharmacol. Exp. Then 254:180–187 (1990).
N. Futaki, S. Takahashi, M. Yokoyama, I. Arai, S. Higuchi, S. Otomo, Prostaglandins, 47:55–59 (1994).
I. Wiesenberg-Boettcher, A. Schweizer, K. Müller, Agents Actions, 26:240–242 (1989).
Preliminary report: C.-S. Li,. C. Boily, C. Black, C. C. Chan, A. W. Ford-Hutchinson, D. Guay, S. Kargman, C. K Lau,. J. Mancini, N. Ouimet, P. Prasit, B. Roy, P. Roy, J. Scheigetz, P. Targari, P. Vickers, E. Wong, R. N. Young, R. Zamboni. Presented at ACS 208th National Meeting, Washington DC, Abstract MEDI 0116 (August 1994).
W. A. Cromlish, B. P. Kennedy, G. O’Neill, P. J. Vickers, E. Wong, J. A. Mancini, PCT International Patent Application Number WO 9414977
C.-C. Chan, C. Black, S. Boyce, C. Brideau, A. W. Ford-Hutchinson, R. Gordon, D. Guay, R. Hill, C.-S. Li, J. Mancini, M. Penneton, P. Prasit, R. Rasori, D. Riendeau, P. Roy, P. Tagari, P. Vickers, E. Wong, I. W. Rodger, J. Pharmacol Exp. Ther. (1995), in press.
I. G. Otterness, P. F. Moore, Methods in Enzymology, 162:320–327, Academic Press, San Diego, California (1988).
L. O Randall,. J. J. Selitto, Arch. Int. Pharmacodyn., 111:409–419 (1957).
J. A. Mancini, G. P. O’Neill, C. Bayly, P. J. Vickers, FEBS Lett., 342:33–37 (1994).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer Science+Business Media New York
About this chapter
Cite this chapter
Lau, C.K. et al. (1997). From Indomethacin to a Selective Cox-2 Inhibitor. In: Honn, K.V., Marnett, L.J., Nigam, S., Jones, R.L., Wong, P.YK. (eds) Eicosanoids and other Bioactive Lipids in Cancer, Inflammation, and Radiation Injury 3. Advances in Experimental Medicine and Biology, vol 407. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-1813-0_11
Download citation
DOI: https://doi.org/10.1007/978-1-4899-1813-0_11
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-1815-4
Online ISBN: 978-1-4899-1813-0
eBook Packages: Springer Book Archive